18F-FDG PET/CT在壶腹部及十二指肠乳头癌术前定性或分期中的价值
回顾性分析58例壶腹部及十二指肠乳头癌(ADPC)与28例良性病变患者的18F-FDG PET/CT,并与增强CT/MRI比较诊断效能、确定性、分期及治疗决策影响。PET/CT诊断ADPC敏感度93.1%、特异度78.6%,特异度高于增强CT/MRI(78.6% vs 35.7%,p=0.001),敏感度相似(93.1% vs 89.6%,p=0.508)。
要点
- PET/CT诊断ADPC敏感度93.1%、特异度78.6%,特异度高于增强CT/MRI。
- PET/CT明确报告率88.4%,高于增强CT/MRI的50.0%,小肿瘤(≤1.5 cm)优势更明显。
- PET/CT发现5例远处转移,影响11例治疗方案,提高28例诊断信心。
关键影像表现/征象
- 18F-FDG PET/CT诊断ADPC的敏感度为93.1%,特异度为78.6%。
- 18F-FDG PET/CT诊断ADPC的特异度高于增强CT/MRI(78.6% vs 35.7%,p=0.001)。
- 18F-FDG PET/CT与增强CT/MRI的敏感度相似(93.1% vs 89.6%,p=0.508)。
- 18F-FDG PET/CT明确报告率高于增强CT/MRI(88.4% vs 50.0%,χ2=29.698,p<0.001),对小肿瘤(≤1.5 cm)尤为明显。
- 18F-FDG PET/CT在5例患者中发现远处转移。
诊断标准与关键数值
- 18F-FDG PET/CT诊断ADPC的敏感度为93.1%,特异度为78.6%。
- 增强CT/MRI诊断ADPC的敏感度为89.6%,特异度为35.7%。
- 18F-FDG PET/CT明确报告率为88.4%,增强CT/MRI为50.0%(χ2=29.698,p<0.001)。
临床应用与阅片要点
- 18F-FDG PET/CT可补充增强CT/MRI,提高ADPC诊断准确性,尤其对≤1.5 cm小肿瘤的诊断确定性更高。
- 18F-FDG PET/CT可发现远处转移并影响治疗决策(11例治疗方案改变,28例诊断信心提高)。
- 作者认为18F-FDG PET/CT在复杂胰十二指肠切除术前的决策过程中起重要作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Diagnosing ampullary and duodenal papillary carcinomas (ADPCs) is challenging. In the present study, we investigated the application value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in the preoperative evaluation of these tumours.
METHODS: 18F-FDG PET/CT images of 58 patients with ADPC and 28 patients with benign disease were retrospectively analysed. Preoperative 18F-FDG PET/CT was compared to contrast-enhanced (CE) CT and magnetic resonance imaging (MRI) in terms of diagnostic efficacy, certainty, staging and impact on treatment decisions.
RESULTS: 18F-FDG PET/CT showed a high sensitivity (93.1%) and a medium specificity (78.6%) for diagnosing ADPC. Compared to CE CT/MRI, 18F-FDG PET/CT had a higher diagnostic specificity (78.6 vs. 35.7%, p = 0.001) but a similar sensitivity (93.1 vs. 89.6%, p = 0.508). 18F-FDG PET/CT provided a much higher diagnostic certainty than CE CT/MRI (definite reports, 88.4 vs. 50.0%, χ2 = 29.698, p < 0.001), especially for small tumours ≤ 1.5 cm, and found distant metastases in five patients. The 18F-FDG PET/CT findings affected the treatment plans of 11 patients and improved the confidence in the diagnoses of 28 patients.
CONCLUSIONS: The present study demonstrated that 18F-FDG PET/CT can supplement CE CT/MRI to provide a more accurate diagnosis for ADPC, and thus, plays an important role in the decision-making process before complicated pancreaticoduodenectomy procedures.
KEY POINTS: • It is a challenge for CT and MRI to diagnose ampullary carcinoma, especially at their early stage. • Our study demonstrated that the benefit of PET/CT was improving the diagnostic confidence for ampullary and duodenal papillary carcinomas. • 18F-FDG PET/CT can change the treatment decision for ampullary and duodenal papillary carcinomas.
引用
- Wen G, Gu J, Zhou W, et al. Benefits of 18F-FDG PET/CT for the preoperative characterisation or staging of disease in the ampullary and duodenal papillary. Eur Radiol. 2020. PMID: 32346795. doi:10.1007/s00330-020-06864-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。